Back to Search Start Over

Exploring the link between inflammatory myopathies and cancer: A comprehensive retrospective analysis in a Colombian cohort.

Authors :
Bolaños JD
Rivera-Londoño R
Hurtado-Bermúdez LJ
Nieto-Aristizábal I
Enriquez KD
Zura-Rodríguez S
Hormaza-Jaramillo A
Aguirre-Valencia D
Source :
Reumatologia clinica [Reumatol Clin (Engl Ed)] 2024 Aug-Sep; Vol. 20 (7), pp. 353-359.
Publication Year :
2024

Abstract

Background: This study investigates the association between inflammatory myopathies (IM), and their correlation with cancer. There are several potential causes behind the association of cancer and inflammatory myopathies. The positivity of specific antibodies for myositis plays a significant role. Our objective is to describe cancer and inflammatory myopathies in Colombia, focusing on demographics, clinical characteristics, and laboratory data.<br />Methods: We retrospectively analyzed 112 IM patients diagnosed at Fundación Valle del Lili in Cali, Colombia, the cases met the EULAR/ACR criteria. Data included demographics, clinical signs, laboratory findings, and malignancy. Malignancy associations were explored using logistic regression. The survival analysis was assessed using Kaplan-Meier curves and the Log-Rank test.<br />Results: Dermatomyositis was the most common subtype (45.5%), with a female predominance (66.1%). Cancer diagnosis occurred in 11.6% of cases, predominantly thyroid cancer. The median time from myopathy onset to cancer diagnosis was 11 months, with 75% of cases within the first year. Bivariate analysis indicated associations between cancer and age, Gottron's papules, digital ulcers, and heliotrope rash. However, multivariate analysis identified age as the only significant malignancy risk factor. Survival analysis showed better rates in younger patients.<br />Conclusion: This study provides into the link between IM and cancer in the Colombian population. Thyroid cancer predominated, with a slightly higher proportion of female cancer diagnoses. Age emerged as a significant risk factor for malignancy. Understanding this association is crucial for early detection and improving patient outcomes related to IM-associated malignancies.<br /> (Copyright © 2024 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.)

Details

Language :
English
ISSN :
2173-5743
Volume :
20
Issue :
7
Database :
MEDLINE
Journal :
Reumatologia clinica
Publication Type :
Academic Journal
Accession number :
39160006
Full Text :
https://doi.org/10.1016/j.reumae.2024.07.004